Price movement over the last 24 hours
AdaptHealth Corp vs Xylem, Inc. — how do they compare? AdaptHealth Corp trades at $10.05 (market cap $1.38B), while Xylem, Inc. trades at $118.36 (market cap $28.68B). The key difference: Xylem, Inc. is far larger — about 20.8× AdaptHealth Corp's market cap, and Xylem, Inc. pays a 1.43% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | XYL | |
|---|---|---|
Market Cap | $1.38B | $28.68B |
Sector | Health | Industrials |
52-Week High | $13.38 | $152.95 |
52-Week Low | $8.68 | $106.34 |
Enterprise Value | $3.33B | $29.93B |
Dividend Yield | — | 1.43% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Xylem (XYL) trades at $120.65, up 2.14% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin improving to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing its position in water technology solutions.
The stock offers upside to the $153.14 consensus price target, driven by steady earnings growth and margin expansion. Risks include execution challenges in a competitive market and potential macroeconomic headwinds affecting industrial demand. Analyst sentiment is mixed but leans positive with 47.5% buy ratings.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →